EMA validates MAA for novel telomerase inhibitor
The European Medicines Agency has validated the Marketing Authorisation Application for imetelstat, a first-in-class telomerase inhibitor as a treatment for transfusion-dependent anaemia in lower...
Source: marketscreener.com